Servier’s Tibsovo receives marketing approval from EC to treat cancer

11 May 2023
www.pharmaceutical-technology.com
Drug ApprovalPhase 3Clinical Result
Servier’s Tibsovo receives marketing approval from EC to treat cancer
Preview
Source: Pharmaceutical Technology
Micrograph of cholangiocarcinoma. Credit: Nephron/ commons.wikimedia.org.
Servier has received marketing authorisation from the European Commission (EC) for Tibsovo (ivosidenib tablets) to treat isocitrate dehydrogenase-1 (IDH1)-mutated acute myeloid leukaemia (AML) and IDH1-mutated cholangiocarcinoma.
Tibsovo is an isocitrate dehydrogenase-1 inhibitorisocitrate dehydrogenase-1 inhibitor indicated to treat IDH1 R132-mutated locally advanced or metastatic cholangiocarcinomaIDH1 R132-mutated locally advanced or metastatic cholangiocarcinoma in adult patients who have previously received a minimum of one line of systemic therapy.
Recommended Reports
Servier’s Tibsovo receives marketing approval from EC to treat cancer
Preview
Source: Pharmaceutical Technology
ReportsLOA and PTSR Model - Docetaxel in Pancreatic Cancer GlobalData
Servier’s Tibsovo receives marketing approval from EC to treat cancer
Preview
Source: Pharmaceutical Technology
ReportsLOA and PTSR Model - Stenoparib in Pancreatic Cancer GlobalData
View all
Along with azacytidine, the therapy is indicated to treat newly diagnosed IDH1 R132-mutated AMLIDH1 R132-mutated AML adult patients who are not eligible to receive standard induction chemotherapy.
It is claimed to be the first and only IDH1-targeted therapy to receive approval in Europe.
Servier Global Product Strategy executive vice-president Philippe Gonnard stated: “IDH1 mutations are major drivers of disease progression in acute myeloid leukaemia and cholangiocarcinoma, which are usually diagnosed at an advanced stage, highlighting the urgent need for a targeted therapeutic option.
“The development of new targeted therapies such as Tibsovo, which works differently from traditional chemotherapies, is now providing treatment options that may increase the life expectancy and quality of life for patients.”
This regulatory approval for Tibsovo to treat cholangiocarcinoma was supported by the data obtained from the ClarIDHy Phase III trial.
Findings showed that the median progression-free survival (PFS) for Tibsovo was 2.7 months and for placebo was 1.4 months.
The EC’s approval in AMLAML was supported by data from the multicentre, double-blind, randomised, placebo-controlled, global AGILE Phase III trial.
Tibsovo is approved in the US as monotherapy to treat IDH1-mutant relapsed or refractory AMLIDH1-mutant relapsed or refractory AML in adult patients.
In May 2022, it was approved as a monotherapy or along with azacytidine for newly diagnosed IDH1-mutant AML adult patients aged 75 years or above, or those who have comorbidities that prevent the usage of intensive induction chemotherapy.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.